Technetium-99m-Sestamibi (99mTc-sestamibi) scintigraphy has been shown to be capable of differentiating patients with multiple myeloma (MM) in remission from those with active disease. We studied 5 patients with MM (2 females and 3 males, age 53±17 years) before and after treatment. 99mTc-sestamibi scintigraphic results were concordant with clinical status.
|Number of pages||2|
|Publication status||Published - 2000|
- 99m Tc-sestamibi
- Multiple myeloma
ASJC Scopus subject areas